Abeona Therapeutics Reports Second Quarter 2019 Financial Results and Business Updates
August 09, 2019 16:15 ET
|
Abeona Therapeutics Inc.
Five patients with MPS IIIB treated in the Transpher B Study of ABO-101 gene therapy Positive interim MPS IIIA data showed preservation of neurocognitive development in youngest patients with robust...
Abeona Therapeutics Receives FDA Fast Track Designation for ABO-202 AAV9 Gene Therapy in CLN1 Disease
June 18, 2019 08:29 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, June 18, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the U.S. Food and Drug...
Abeona Therapeutics Announces FDA Clearance of Investigational New Drug Application for ABO-202 Gene Therapy in CLN1 Disease
May 21, 2019 08:00 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 21, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company is cleared to...
Abeona Therapeutics to Present Data for ABO-401 in Cystic Fibrosis and Retinal Disorders at the American Society of Gene and Cell Therapy Annual Meeting
April 15, 2019 14:41 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, April 15, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that new data demonstrating...
Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease
April 20, 2018 08:15 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, April 20, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and...
Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease
March 15, 2018 08:45 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, March 15, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-202 Gene Therapy Program in Infantile Batten Disease
February 12, 2018 08:45 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Reports Third Quarter 2017 Financial Results and Recent Business Highlights
November 15, 2017 08:25 ET
|
Abeona Therapeutics Inc.
Investor Conference Call to be held Monday, November 20th at 10:00 am ETGlobal enrollment continues in ABO-102 trial for MPS IIIAScreening initiated in ABO-101 Phase 1/2 trial for MPS IIIBPivotal...
Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-201 Juvenile Batten Disease Gene Therapy Program
June 29, 2017 08:15 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, June 29, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
Abeona Announces Rare Disease Gene Therapy Symposium with the New York Academy of Sciences
April 05, 2017 07:43 ET
|
Abeona Therapeutics Inc
Company CEO to Co-Chair Symposium being held on April 11th in NYC NEW YORK and CLEVELAND, April 05, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage...